Novel treatments for castration-resistant prostate cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference23 articles.
1. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2);Scher;J Clin Oncol,2008
2. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer;de Bono;Clin Cancer Res,2008
3. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A Canadian randomized trial with palliative end-points;Tannock;J Clin Oncol,1996
4. Hydrocortisone with or without mitoxantrone in men with with hormone refractory prostate cancer: results of Cancer and Leukemia Group B 9182 study;Kantoff;J Clin Oncol,1999
5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;NEnglJMed,2004
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer;International Journal of Biological Sciences;2014
2. Scoparone Exerts Anti-Tumor Activity against DU145 Prostate Cancer Cells via Inhibition of STAT3 Activity;PLoS ONE;2013-11-15
3. Genitourinary Cancer;Side Effects of Medical Cancer Therapy;2012-10-31
4. Stratégie thérapeutique dans le cancer de la prostate;Actualités Pharmaceutiques;2012-10
5. New Perspectives in Advanced Genitourinary Malignancies;Tumori Journal;2012-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3